

Angiogenesis: A Key Target in Oncology

Barcelona, Spain, October 30-31, 2009

Chairmen: **Prof Eric Van Cutsem and Prof Emile Voest**
Course coordinator: **Dr Matti Aapro**

FRIDAY, OCTOBER 30, 2009

Registration opens at 10:00 am. Lunch buffet available from 12:00

- 13:30-13:40 Introduction
Eric Van Cutsem, Emile Voest, Matti Aapro
- Session I: Basic knowledge**
Session chair E. Van Cutsem
- 13:40-14:05 Understanding the process of angiogenesis and cancer
Peter Carmeliet, Belgium
- 14:10-14:35 Predictive markers for activity and toxicity
Emile Voest, The Netherlands
- 14:40-15:05 Anti-angiogenic agents on the horizon
Henk Verheul, The Netherlands
- 15:10-15:35 Tumor rebound: is there clinical evidence?
David Miles, United Kingdom
- 15:40-16:05 Key Note Lecture: Mechanism of resistance to angiogenesis inhibitors
Napoleone Ferrara, USA
- 16:05-16:30 **Coffee break**
- Session II: Imaging tools for determining the activity of angiogenesis inhibitors**
Session chair M. Aapro
- 16:30-16:50 MRI
Anwar Padhani, United Kingdom
- 16:55-17:15 Ultrasound
Nathalie Lassau, France
- Session III: Lung and Prostate cancer**
Session chair J. Bellmunt
- 17:20-17:40 Angiogenesis inhibition in Prostate cancer
Joaquim Bellmunt, Spain
- 17:45-18:05 Angiogenesis inhibition in Lung cancer
Jürgen Wolf, Germany
- 18:10-18:15 Adjourn day 1

Angiogenesis: A Key Target in Oncology
Barcelona, Spain, October 30-31, 2009

SATURDAY, OCTOBER 31, 2009

Session IV: RCC and Breast cancer

Session chair M. Aapro

- 08:30-08:50 Angiogenesis inhibition in RCC
Camillo Porta, Italy
- 08:55-09:15 Other biologicals, incl. mTOR in RCC
Joaquim Bellmunt, Spain
- 09:20-09:40 Angiogenesis inhibition in Breast cancer
Nadia Harbeck, Germany

09:45-10:15 **Coffee break**

Session V: GI-Cancer

Session chair M. Ducreux

- 10:15-10:45 Angiogenesis inhibition in metastatic colorectal cancer
Eric Van Cutsem, Belgium
- 10:50-11:10 Angiogenesis inhibition & surgery in colorectal cancer
Theo Ruers, The Netherlands
- 11:15-11:35 Angiogenesis inhibition in adjuvant treatment of colorectal cancer
Aimery De Gramont, France
- 11:40-12:00 Angiogenesis inhibition in gastric cancer
Michel Ducreux, France

Session VI: Emerging Indications and Drugs

Session chair E. Voest

- 12:05-12:20 Angiogenesis inhibition in Glioblastoma
Roger Stupp, Switzerland
- 12:25-12:40 Angiogenesis inhibition in Ovarian cancer
Andrew Clamp, United Kingdom
- 12:45-13:00 Angiogenesis inhibition in combination with Radiotherapy
Christopher Willett, USA
- 13:05-13:20 Differential Drug safety in anti-angiogenic therapy
Jean-Philippe Spano, France
- 13:30-13:50 Learning Assessments: Attendees answer 15 questions based on the course.
- 14:00-15:00 Lunch-buffet and certificate delivery